GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.01 USD | -0.95% |
|
+3.22% | -17.28% |
| May. 14 | Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM | |
| May. 09 | Declaration of Voting Results by Gilead Sciences | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 27.6B | Sales 2025 * | 27.98B | Capitalization | 83.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.68 x |
| Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.44 x |
| P/E ratio 2024 * |
192
x | P/E ratio 2025 * |
13
x | Employees | 18,000 |
| Yield 2024 * |
4.61% | Yield 2025 * |
4.84% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | -0.95% | ||
| 1 week | +3.22% | ||
| Current month | +2.78% | ||
| 1 month | -1.09% | ||
| 3 months | -8.67% | ||
| 6 months | -10.70% | ||
| Current year | -17.28% |
1 week
64.67
68.37
1 month
64.3368.37
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +9.50% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 67.01 | -0.95% | 7,532,064 |
| 24-05-14 | 67.65 | +0.16% | 4,356,239 |
| 24-05-13 | 67.54 | +2.40% | 6,736,457 |
| 24-05-10 | 65.96 | +2.14% | 8,733,211 |
| 24-05-09 | 64.58 | -0.52% | 6,048,572 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.01
USD
Average target price
82.93
USD
Spread / Average Target
+23.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.28% | 83.48B | |
| +35.01% | 709B | |
| +30.83% | 595B | |
| -2.60% | 367B | |
| +20.83% | 334B | |
| +5.69% | 289B | |
| +14.43% | 239B | |
| +9.28% | 211B | |
| -3.19% | 203B | |
| +10.77% | 171B |
- Stock Market
- Equities
- GILD Stock
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**
